MedPage Today

Reassessing Cardiac Amyloidosis: Sex Disparities in Diagnostic Thresholds

Investigators in Italy report that CA may be underdiagnosed in women due to sex differences in left ventricular wall thickness. Current diagnostic criteria may not accurately reflect disease severity ...
MedPage Today

Rare Forms of Cardiac Amyloidosis: About the Diagnostic Clues

"These forms of cardiac amyloidosis are rare but increasingly recognized. For the first time, patients with both forms of amyloidosis have undergone deep phenotyping using cardiac biomarkers, 12-lead ...
Healio

ACC: Early recognition, diagnosis of cardiac amyloidosis critical

A new expert consensus decision pathway published by the American College of Cardiology highlights the importance of recognizing and diagnosing cardiac amyloidosis at an early stage to allow the most ...
Pharmabiz

Attralus’ pan-amyloid diagnostic PET imaging candidate, 124I-evuzamitide for cardiac amyloidosis receives US FDA breakthrough therapy designation

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative products to improve the lives of patients with systemic amyloidosis, announced that its investigational diagnostic ...
Yahoo Finance

Attralus Announces Enrollment of First Patient in Phase 3 Trial for the Pan-Amyloid Diagnostic 124I-evuzamitide (AT-01) for Cardiac Amyloidosis

124 I-evuzamitide has received Breakthrough Therapy Designation from the Food and Drug Administration (FDA) for PET imaging in patients with suspected or known cardiac amyloidosis. 124 I-evuzamitide ...
Mena FN

Attralus Announces Enrollment Of First Patient In Phase 3 Trial For The Pan-Amyloid Diagnostic 124I-Evuzamitide (AT-01) For Cardiac Amyloidosis

NAPLES, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative products to improve the lives of patients with systemic amyloidosis ...
Yahoo Finance

Attralus Receives Breakthrough Therapy Designation for its Pan-Amyloid Diagnostic PET Imaging Candidate 124I-evuzamitide (AT-01) for Cardiac Amyloidosis

BURLINGAME, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative products to improve the lives of patients with systemic ...